EGFR is overexpressed in prostate cancer, in 31–48% of bladder cancer and 25–77% of colon and rectal cancer as well [33], which might reduce the specificity for the detection of PSCC by using imaging modalities with antibodies directed against EGFR. This evidence concerns the gene EGFR and urinary bladder carcinoma.